Trial reportThe American journal of pathology2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
Trial report in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00002823 (A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A large-scale trial evaluating adjuvant chemotherapy after curative resection of non-small cell lung cancer
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.Molecular biology reports · 2012Pooled it
- Trial
- Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.Molecular oncology · 2014Trial
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- [Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy in Postoperative Patients with Stage I Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Prognostic Value of Chromatin Structure Typing in Early-Stage Non-Small Cell Lung Cancer.Cancers · 2023Article
- Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation.Advanced drug delivery reviews · 2021Review
- Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular MarkersJournal of oncology · 2021Article
- A new normalization for Nanostring nCounter gene expression data.Nucleic acids research · 2019Article
- Prognostic and predictive biomarkers post curative intent therapy.Annals of translational medicine · 2017Review
- [Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Review
- Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.Disease markers · 2015Article
- Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Article
- [Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- [Advance of postoperative adjuvant therapy in non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.The oncologist · 2014Article
- Prognostic value of microRNA expression in operable non-small cell lung cancer patients.British journal of cancer · 2014Article
- Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.Translational lung cancer research · 2013Review
- A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.Journal of personalized medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
The excision repair cross completing group 1 gene product (ERCC1) and the regulatory subunit of ribonucleotide reductase (RRM1) have been reported as being prognostic of outcome and predictive of therapeutic efficacy in patients with non-small cell lung cancer. Routinely processed surgical specimens from 784 patients from the International Adjuvant Lung Trial were arrayed as tissue microarrays. In situ protein levels were scored with an automated, quantitative analysis system, dichotomized into high and low marker categories, and analyzed for associations with patients' characteristics, survival, and benefit from adjuvant chemotherapy. Scores for both markers were significantly associated with contributing center (P < 0.001) and skewed, with the bulk of scores being low. High scores were more frequent in women for ERCC1 and RRM1 and in older patients and those with adenocarcinoma for RRM1. Low ERCC1 scores indicated significant benefit from adjuvant chemotherapy [hazard ratio (HR) = 0.73 for chemotherapy versus control, P = 0.02]. Although all other survival associations were not statistically significant, low RRM1 scores trended to indicate benefit from adjuvant chemotherapy (HR = 0.84, P = 0.25), and ERCC1 scores were marginally prognostic of survival (HR = 0.77 for high versus low scores, P = 0.10). We conclude that contributing center and specimen quality substantially affect the levels of both markers. Future trials should incorporate the collection and processing of tumor specimens prospectively on standardized protocols to better reveal the impact of biomarkers on clinically relevant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.